14.Subsequent Event

In October 2018, we announced an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. (“Kissei”) to develop and commercialize fostamatinib in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. Under the terms of the agreement, we will receive an upfront cash payment of $33 million with the potential for up to an additional $147 million in development and commercial milestone payments.  We will also receive product transfer price payments in the mid to upper twenty percent range based on tiered net sales for exclusive supply of TAVALISSE.  We retain the global rights to develop fostamatinib and the global rights, excluding these Asian countries, to commercialize fostamatinib for any indication.